Silo Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on August 18, 2021, covering events occurring on August 17, 2021. The filing addresses a specific corporate event under Item 8.01 (Other Events) regarding the Company's investment in DatChat, Inc.
Key Financial Metrics
The filing text does not provide a clear value for Silo Pharma's revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the valuation of a specific equity holding.
- Investment Holding: Silo Pharma owns 1,000,000 shares of restricted common stock of DatChat, Inc.
- Related Event: DatChat, Inc. completed its initial public offering (IPO) on August 17, 2021.
- IPO Details: DatChat offered 2,891,567 units (common stock and Series A warrants) at a public offering price of $4.15 per unit.
Material Changes
The material change reported is the public listing of DatChat, Inc., which alters the nature and potential liquidity of Silo Pharma's restricted stock investment. No other material changes to Silo Pharma's operations or financial condition are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for Silo Pharma. It does not disclose specific risks or contingencies beyond the standard context of holding restricted stock in a newly public company.
Key Facts for Investor Verification
- Verify the current market price of DatChat, Inc. common stock to assess the fair value of Silo Pharma's 1,000,000 share holding.
- Confirm the specific restrictions and lock-up periods applicable to Silo Pharma's DatChat shares.
- Review Silo Pharma's most recent 10-K or 10-Q for comprehensive financial data, as this 8-K does not contain financial statements.